Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Revenue Change due to Price

Revenue Change due to Price % Chg.

Revenue Change due to Volume

Revenue Change due to Volume % Chg.

Revenue Change due to FX

Revenue Change due to FX % Chg.

Key Performance Indicators

US Revenue

US Revenue % Chg.

US Revenue Common Size

Europe Revenue

Europe Revenue % Chg.

Europe Revenue Common Size

Japan Revenue

Japan Revenue % Chg.

Japan Revenue Common Size

China Revenue

China Revenue % Chg.

China Revenue Common Size

Other Foreign Countries Revenue

Other Foreign Countries Revenue % Chg.

Other Foreign Countries Revenue Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Baqsimi Revenue

Baqsimi Revenue % Chg.

Baqsimi Revenue Common Size

Basaglar Revenue

Basaglar Revenue % Chg.

Basaglar Revenue Common Size

Glucagon Revenue

Glucagon Revenue % Chg.

Glucagon Revenue Common Size

Humalog Revenue

Humalog Revenue % Chg.

Humalog Revenue Common Size

Humulin Revenue

Humulin Revenue % Chg.

Humulin Revenue Common Size

Jardiance Revenue

Jardiance Revenue % Chg.

Jardiance Revenue Common Size

Mounjaro Revenue

Mounjaro Revenue % Chg.

Mounjaro Revenue Common Size

Trajenta Revenue

Trajenta Revenue % Chg.

Trajenta Revenue Common Size

Trulicity Revenue

Trulicity Revenue % Chg.

Trulicity Revenue Common Size

Zepbound Revenue

Zepbound Revenue % Chg.

Zepbound Revenue Common Size

Other Cardiometabolic Health Revenue

Other Cardiometabolic Health Revenue % Chg.

Other Cardiometabolic Health Revenue Common Size

Cardiometabolic Health Revenue

Cardiometabolic Health Revenue % Chg.

Cardiometabolic Health Revenue Common Size

Oncology Revenue

Oncology Revenue % Chg.

Oncology Revenue Common Size

Immunology Revenue

Immunology Revenue % Chg.

Immunology Revenue Common Size

Neuroscience Revenue

Neuroscience Revenue % Chg.

Neuroscience Revenue Common Size

Other Product Revenue

Other Product Revenue % Chg.

Other Product Revenue Common Size

Endocrinology Revenue

Endocrinology Revenue % Chg.

Endocrinology Revenue Common Size

Cardiovascular Revenue

Cardiovascular Revenue % Chg.

Cardiovascular Revenue Common Size

Animal Health Revenue

Animal Health Revenue % Chg.

Animal Health Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	Sep '25	Jun '25
Baqsimi Revenue	—	—
Basaglar Revenue	162.2	145
Glucagon Revenue	—	—
Humalog Revenue	599.1	503.1
Humulin Revenue	176.6	175.2
Jardiance Revenue	959	690
Mounjaro Revenue	6,515.1	5,198.9
Trajenta Revenue	71.3	91.8
Trulicity Revenue	1,051.8	1,092.2
Zepbound Revenue	3,588.1	3,381.4
Other Cardiometabolic Health Revenue	54.5	65.4
Cardiometabolic Health Revenue	13,177.9	11,342.9
Oncology Revenue	2,407.6	2,413.6
Immunology Revenue	1,362.4	1,255.6
Neuroscience Revenue	315.7	344
Other Product Revenue	337.2	201.5
Other Revenue	—	0.1
Total Revenue	17,600.8	15,557.7

Revenue by Geography	Sep '25	Jun '25
US Revenue	11,300	10,814.2
Europe Revenue	3,498.1	2,574.4
Japan Revenue	554.7	521
China Revenue	560.4	465.9
Other Foreign Countries Revenue	1,687.7	1,182.1
Other Revenue by Geography	-0.1	0.1
Total Revenue by Geography	17,600.8	15,557.7

Key Performance Indicators	Sep '25	Jun '25
Revenue Change due to Price	-10%	-6%
Revenue Change due to Volume	62%	42%
Revenue Change due to FX	2%	1%